Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1997 1
2001 2
2002 2
2003 1
2004 2
2005 1
2006 1
2007 2
2008 1
2009 2
2010 4
2011 5
2012 3
2013 6
2014 3
2016 3
2017 1
2018 1
2019 1
2020 9
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Hussain RM, et al. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Expert Opin Investig Drugs. 2019. PMID: 31513439 Review.
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Activation of Tie-2 receptor via Ang-1 maintains vascular stability to limit exudation. ...AKB-97 …
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD …
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM, Ciulla TA. Hussain RM, et al. Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12. Expert Opin Biol Ther. 2016. PMID: 26674182 Free article. Review.
INTRODUCTION: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators. ...
INTRODUCTION: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and …
Anti-integrin therapy for retinovascular diseases.
Bhatwadekar AD, Kansara V, Luo Q, Ciulla T. Bhatwadekar AD, et al. Expert Opin Investig Drugs. 2020 Sep;29(9):935-945. doi: 10.1080/13543784.2020.1795639. Epub 2020 Sep 9. Expert Opin Investig Drugs. 2020. PMID: 32657172 Review.
Current clinical candidates include risuteganib, THR-687, and SF-0166, which have shown promise in treating diabetic macular edema (DME) and/or age-related macular degeneration (AMD) in early clinical studies. ...EXPERT OPINION: Anti-integrin therapies show potential in tr …
Current clinical candidates include risuteganib, THR-687, and SF-0166, which have shown promise in treating diabetic macular edema (D …
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Diabetic Retinopathy Clinical Research Network, et al. Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28. Ophthalmology. 2010. PMID: 20427088 Free PMC article. Clinical Trial.
OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). DESIGN: Multicenter, randomized clinical trial. ...
OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alon …
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial.
Yeh S, Khurana RN, Shah M, Henry CR, Wang RC, Kissner JM, Ciulla TA, Noronha G; PEACHTREE Study Investigators. Yeh S, et al. Ophthalmology. 2020 Jul;127(7):948-955. doi: 10.1016/j.ophtha.2020.01.006. Epub 2020 Jan 10. Ophthalmology. 2020. PMID: 32173113 Free article. Clinical Trial.
Patients were required to have a best-corrected visual acuity (BCVA) of 5 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent, 20/800) and 70 or fewer ETDRS letters read (Snellen equivalent, 20/40) in the study eye. ...
Patients were required to have a best-corrected visual acuity (BCVA) of 5 or more Early Treatment Diabetic Retinopathy Study (ETDRS) …
Ocular perfusion abnormalities in diabetes.
Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, Martin B. Ciulla TA, et al. Acta Ophthalmol Scand. 2002 Oct;80(5):468-77. doi: 10.1034/j.1600-0420.2002.800503.x. Acta Ophthalmol Scand. 2002. PMID: 12390156 Free article. Review.
PURPOSE: To review the role of ocular perfusion in the pathophysiology of diabetic retinopathy, one of the leading causes of irreversible blindness in the industrialized world. ...RESULTS: Hyperglycaemia leads to a wide variety of vascular abnormalities at the microvascula …
PURPOSE: To review the role of ocular perfusion in the pathophysiology of diabetic retinopathy, one of the leading causes of irrevers …
RNA therapeutics for retinal diseases.
Gemayel MC, Bhatwadekar AD, Ciulla T. Gemayel MC, et al. Expert Opin Biol Ther. 2020 Dec 16:1-11. doi: 10.1080/14712598.2021.1856365. Online ahead of print. Expert Opin Biol Ther. 2020. PMID: 33307874
Another form of RNAi involves short hairpin RNA (shRNA). In age-related macular degeneration (AMD) and diabetic retinopathy (DR), miRNA has been implicated in the regulation of angiogenesis, oxidative stress, immune response, and inflammation. ...
Another form of RNAi involves short hairpin RNA (shRNA). In age-related macular degeneration (AMD) and diabetic retinopathy (DR), miR …
A practice-based research network focused on comparative effectiveness research in type 2 diabetes management.
Anderson JE, Rhinehart AS, Reid TS, Cuddihy RM, Vlajnic A, Dalal MR, Gemmen E, Johnstone B, Abbaszadeh B, Reed J, Sheller J, Stewart J, Mozaffari E; Diabetes FORWARD Investigators. Anderson JE, et al. Postgrad Med. 2013 May;125(3):172-80. doi: 10.3810/pgm.2013.05.2658. Postgrad Med. 2013. PMID: 23748518
METHODS: Diabetes FORWARD (Foundation of Real-World Assessment and Research in Diabetes) is a North American research platform being organized to conduct longitudinal, noninterventional investigations of an anticipated 10,000 patients with type 2 diabetes …
METHODS: Diabetes FORWARD (Foundation of Real-World Assessment and Research in Diabetes) is a North American research platform …
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
Bhatwadekar AD, Kansara VS, Ciulla TA. Bhatwadekar AD, et al. Expert Opin Investig Drugs. 2020 Mar;29(3):237-244. doi: 10.1080/13543784.2020.1723078. Epub 2020 Jan 31. Expert Opin Investig Drugs. 2020. PMID: 31985300 Free PMC article. Review.
Introduction: Plasma kallikrein is a mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. ...
Introduction: Plasma kallikrein is a mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of …
Pharmacotherapy for diabetic retinopathy.
Comer GM, Ciulla TA. Comer GM, et al. Curr Opin Ophthalmol. 2004 Dec;15(6):508-18. doi: 10.1097/01.icu.0000143685.60479.3b. Curr Opin Ophthalmol. 2004. PMID: 15523197 Review.
PURPOSE OF REVIEW: Diabetic retinopathy (DR) is a potentially visually devastating complication of chronic hyperglycemia and other associated systemic abnormalities. ...RECENT FINDINGS: Phase II and III clinical studies involving antivascular endothelial growth factor (VEG …
PURPOSE OF REVIEW: Diabetic retinopathy (DR) is a potentially visually devastating complication of chronic hyperglycemia and other as …
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page